A peer-reviewed paper in the Journal of Cancer Science & Therapy (2018) reported an investigation of metronomic photodynamic therapy for local prostate cancer.
In this ethics-approved Phase 1 prostate cancer trial, patients were treated with targeted photodynamic therapy and coupled ultrasound energies, using chlorophyll-based photosensitisers given orally or sublingually. The “metronomic” technique repeats the photosensitiser and energy over set time intervals.
Intra-treatment fluorescent photography of the prostate and urinary proteomic studies were used as measurable parameters. As reported in the paper, the dataset covered 666 treatment episodes and 333 photosensitiser doses with three to five years of patient follow-up, and the authors described the fluorescent-photographic and proteomic findings, including immune-system results.